ECS Botanics Holdings Ltd engages in the cultivation, manufacture, and sale of medicinal cannabis products.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.037|
|52 Week High||AU$0.023|
|52 Week Low||AU$0.078|
|1 Month Change||-13.95%|
|3 Month Change||-9.76%|
|1 Year Change||12.12%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-43.08%|
Recent News & Updates
ECS Botanics Holdings (ASX:ECS) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|ECS||AU Pharmaceuticals||AU Market|
Return vs Industry: ECS exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: ECS underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: ECS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ECS's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
ECS Botanics Holdings Ltd engages in the cultivation, manufacture, and sale of medicinal cannabis products. It also retails hemp wellness and food products; and engages in the agriculture business. The company is based in Launceston, Australia.
ECS Botanics Holdings Fundamentals Summary
|ECS fundamental statistics|
Is ECS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ECS income statement (TTM)|
|Cost of Revenue||AU$1.16m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0048|
|Net Profit Margin||-315.30%|
How did ECS perform over the long term?See historical performance and comparison
Is ECS Botanics Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ECS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ECS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ECS is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: ECS is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ECS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ECS is good value based on its PB Ratio (2x) compared to the AU Pharmaceuticals industry average (3.3x).
How is ECS Botanics Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ECS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ECS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ECS's is expected to become profitable in the next 3 years.
Revenue vs Market: ECS's revenue (62.9% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: ECS's revenue (62.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ECS's Return on Equity is forecast to be high in 3 years time
How has ECS Botanics Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ECS is currently unprofitable.
Growing Profit Margin: ECS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ECS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ECS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ECS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: ECS has a negative Return on Equity (-25.37%), as it is currently unprofitable.
How is ECS Botanics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: ECS's short term assets (A$8.0M) exceed its short term liabilities (A$1.4M).
Long Term Liabilities: ECS's short term assets (A$8.0M) exceed its long term liabilities (A$18.2K).
Debt to Equity History and Analysis
Debt Level: ECS's debt to equity ratio (0.01%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ECS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ECS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ECS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 55.2% each year
What is ECS Botanics Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ECS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ECS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ECS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ECS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ECS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Alexander Keach, also known as Alex, is the Founder at ECS Botanics Holdings Ltd. He is also the Managing Director at ECS Botanics Holdings Ltd since July 11, 2019. He was employed in many roles at Bel...
CEO Compensation Analysis
Compensation vs Market: Alex's total compensation ($USD144.73K) is below average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Alex's compensation has been consistent with company performance over the past year.
Experienced Management: ECS's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: ECS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ECS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 55.1%.
ECS Botanics Holdings Ltd's employee growth, exchange listings and data sources
- Name: ECS Botanics Holdings Ltd
- Ticker: ECS
- Exchange: ASX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$35.362m
- Shares outstanding: 906.73m
- Website: https://ecsbotanics.com.au
- ECS Botanics Holdings Ltd
- 94 Green Rises Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:03|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.